Award
NIH Reporter #1R01DK149654-01
Targeting Intracellular CD38 to Reduce Ischemia-Reperfusion Injury in Liver Transplantation
Recipient
Ohio State University, Columbus, OH
Award Amount
$807,563.00
Ceiling
$807,563.00
Awarded
August 24, 2026
Identifier
1R01DK149654-01
A research project funded by NIDDK, NIH to develop selective inhibitors of type III CD38 to reduce ischemia-reperfusion injury in liver transplantation, aiming to improve transplant success and address ischemic injuries affecting millions.
Description
This project aims to characterize and test the therapeutic potential of inhibiting the enzyme CD38, especially type III CD38, to preserve donor organ integrity and enhance transplantation outcomes. It focuses on developing selective inhibitors targeting type III CD38 to improve liver transplantation outcomes and address ischemic injuries.